NCE-1 Intelligence & Market Opportunity

Augtyro

Repotrectinib

Anticancer

Capsule

Augtyro is an oral treatment for ROS1-positive non-small cell lung cancer and NTRK fusion–positive tumors. It blocks key cancer-driving proteins to help slow tumor growth, especially in patients who’ve tried other therapies.

Approval Date

15-Nov-23

NCE-1 Date

15-Nov-27

NCE Date

15-Nov-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.6321

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

132

2027

189

2028

241

2029

288

2030

331

2031

367

2032

400

Molecule profile

Details & specifications

Molecule

Repotrectinib

Innovator

BRISTOL MYERS SQUIBB CO

Dosage Form

Capsule

Strength

40 mg

Therapeutic Category

Anticancer

Usage

To treat ROS1-positive non-small cell lung cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.